Phuturdex › Diseases › Insulin resistance
Drugs in development · updated 30 October 2026
Insulin resistance: drugs in development
As of 30 October 2026 there are 43 active clinical trials (recruiting or ongoing, phases I–III) on 41 drugs for insulin resistance. 13 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| TributyrinGlycerol Tributyrate | III | 1 | NCT07503548 |
| Alpha Lipoic Acid | II | 1 | NCT05713799 |
| CIR-0602K | II | 1 | NCT07186660 |
| Dextrin | II | 1 | NCT07884058 |
| EvexomostatSDX-7320 | I–II | 1 | NCT05455619 |
| IGOB131 | II | 1 | NCT07884058 |
| MOTS-c | II | 1 | NCT07505745 |
| [1-13C] sodium acetate | I | 1 | NCT06354088 |
| Deuterated water | I | 1 | NCT07403604 |
| Glucose20% D-glucose | I | 1 | NCT06558422 |
| Maridebart cafraglutide | I | 1 | NCT07160257 |
| Para-aminohippuric Acid | I | 1 | NCT01426529 |
| Retatrutide | I | 1 | NCT06982859 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| MetforminRiomet Er®, Glumetza® | III | 8 | NCT04578652 |
| SemaglutideWegovy, Rybelsus | II–III | 6 | NCT06387199 |
| EmpagliflozinJardiance | III | 2 | NCT06894784 |
| Insulin Degludec InjectionTresiba® | III | 1 | NCT06767748 |
| TirzepatideZepbound, Mounjaro | II | 3 | NCT07734870 |
| GlucagonGvoke Kit®, Gvoke Hypopen® | I–II | 2 | NCT07300982 |
| ColchicineColchicin, Lodoco® | II | 1 | NCT07247734 |
| MetreleptinMyalept®, Myalepta® | II | 1 | NCT00085982 |
| MirabegronMyrbetriq, Betmiga® | II | 1 | NCT05713799 |
| PegvisomantSomavert® | II | 1 | NCT05470504 |
| Sacubitril | II | 1 | NCT04055428 |
| Sodium BicarbonateSodium Bicarbonate In Plastic Container® | II | 1 | NCT04984226 |
| ValsartanPrexxartan®, Diovan® | II | 1 | NCT04055428 |
| VericiguatVerquvo® | II | 1 | NCT06320951 |
| AlpelisibBYL719, Vijoice® | I | 2 | NCT07778524 |
Sorted by most advanced phase and number of active trials. Showing 15 of 28 drugs.
All 41 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Metabolic syndrome 12 drugs
- Obesity 233 drugs
- Overweight 139 drugs
- Hyperlipidemia 26 drugs
- Alzheimer's disease 157 drugs
- Cognitive dysfunction 94 drugs
- Dementia 54 drugs
- Klinefelter's syndrome 4 drugs
- Infertility 24 drugs
- Gestational diabetes 9 drugs
- Acquired Immunodeficiency Syndrome 61 drugs
- Human body weight 13 drugs
Broader categories
- Nutritional and metabolic diseases 5 drugs
- Glucose metabolism disease 12 drugs
- Metabolic disease 30 drugs
- Hyperinsulinism 14 drugs
- Endocrine system disease 19 drugs
- Nutrition disorder 10 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D007333 “Insulin Resistance”.